+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Drugs Market Research Reports

Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025 - Product Thumbnail Image

Alpha-1 Antitrypsin Deficiency- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Pulmonary Alveolar Proteinosis - Pipeline Insight, 2025 - Product Thumbnail Image

Pulmonary Alveolar Proteinosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nasal Polyposis - Pipeline Insight, 2025 - Product Thumbnail Image

Nasal Polyposis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 220 Pages
  • Global
From
Cystic Fibrosis - Pipeline Insight, 2025 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 100 Pages
  • Global
From
Tuberculosis - Pipeline Insight, 2025 - Product Thumbnail Image

Tuberculosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Nosocomial Pneumonia - Pipeline Insight, 2025 - Product Thumbnail Image

Nosocomial Pneumonia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Pertussis- Pipeline Insight, 2025 - Product Thumbnail Image

Pertussis- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Pneumococcal Pneumonia - Pipeline Insight, 2025 - Product Thumbnail Image

Pneumococcal Pneumonia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Pseudomonas Aeruginosa-Induced Lung Injury - Pipeline Insight, 2025 - Product Thumbnail Image

Pseudomonas Aeruginosa-Induced Lung Injury - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Interstitial Lung Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Interstitial Lung Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
Cough In Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight,2025 - Product Thumbnail Image

Cough In Idiopathic Pulmonary Fibrosis (IPF) - Pipeline Insight,2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Fungal Pneumonia - Pipeline Insight, 2025 - Product Thumbnail Image

Fungal Pneumonia - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Severe Asthma - Pipeline Insight, 2025 - Product Thumbnail Image

Severe Asthma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Eosinophilic Asthma - Pipeline Insight, 2025 - Product Thumbnail Image

Eosinophilic Asthma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Non-cystic Fibrosis Bronchiectasis - Pipeline Insight, 2025 - Product Thumbnail Image

Non-cystic Fibrosis Bronchiectasis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics. The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more